RxDoctor Payments Data

Lauren Agnello, PA

Physician Assistant · Bronx, NYNPI 1336705052

Payments from drug & device makers

$4,240in general payments, 2019–2025

Across 132 payments — averaging $32.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Janssen Products, LP$2K
  • Viiv Healthcare Company$383
  • AbbVie$167
  • Madrigal Pharmaceuticals$147
  • Merck$125

What the payments were for

  • Food & beverage$4,05596%
  • Education$1854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,240 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$5,632
Medicare patients
15
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala280$1,080,294
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf78$360,736
GenvoyaElviteg/Cob/Emtri/Tenof Alafen35$162,985
TivicayDolutegravir Sodium75$156,947
TriumeqAbacavir/Dolutegravir/Lamivudi32$119,258
DescovyEmtricitabine/Tenofov Alafenam44$90,787
CabenuvaCabotegravir/Rilpivirine15$89,773
DovatoDolutegravir Sodium/Lamivudine25$67,821
OdefseyEmtricitab/Rilpiviri/Tenof Ala20$67,448
PrezcobixDarunavir/Cobicistat26$60,914
Isentress HdRaltegravir Potassium13$24,874
JardianceEmpagliflozin18$19,315
VemlidyTenofovir Alafenamide11$15,199
EliquisApixaban16$14,282
Atovaquone11$5,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq, Cabenuva, Dovato$383$433,799147 claims
Janssen Products, LPSymtuza$1,677$360,73678 claims
Johnson & JohnsonPrezcobix$1,741$60,91426 claims
MerckIsentress Hd$125$24,87413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →